Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake
Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi have reported a beneficial ownership of 18,557,543 common shares, representing a 9.4% stake in Arbutus Biopharma Corporation (NASDAQ: ABUS). This stake is held through two funds: Two Seas Global (Master) Fund LP and Two Seas LNP Opportunities (Master) Fund LP. The reporting persons have sole voting and dispositive power over these shares, calculated based on 196,947,757 common shares outstanding as of March 31, 2026.
APR 15·GlobeNewswire▲
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Arbutus Biopharma Corporation announced that the U.S. FDA has granted Fast Track designation for imdusiran, a drug for chronic hepatitis B. This designation will facilitate the development and expedited review of imdusiran, which has shown potential to achieve functional cure in trials. The company plans to work closely with the FDA to advance the drug, addressing a significant unmet medical need for the over 250 million people affected by chronic HBV worldwide.
APR 14·Stock Titan→
Whitefort outlines 8.1% Arbutus Biopharma (ABUS) stake in amended 13D
Whitefort Capital and its related entities have reported an 8.1% beneficial ownership in Arbutus Biopharma (ABUS), acquiring 15,794,261 common shares for approximately $41.8 million. This information was disclosed in an amended form Schedule 13D. The filing provides details on the source of funds, ownership structure, and an exhibit listing all transactions over the past 60 days.
